Salvia BioElectronics raises EUR 26M (USD 31M) to develop innovative neurostimulation therapy for chronic migraine

Salvia BioElectronics B.V., a neurostimulation platform
company targeting chronic migraine, today announced it has raised EUR 26M in new financing from new and
existing investors. The Series A investment round was led by Panakès Partners, INKEF Capital and SHS
Gesellschaft für Beteiligungsmanagement with participation from BOM Brabant Ventures, Thuja Capital and
Dolby Family Ventures. The total raised includes a EUR 5M deferred risk-bearing Innovation Credit from the
Netherlands Enterprise Agency (RVO, part of the Dutch ministry of Economic Affairs and Climate Policy). Salvia
BioElectronics will use the funds to develop a unique neuromodulation technology capable of addressing
known neural targets in chronic migraine and provide its therapy to those suffering from debilitating
headaches.

Read more….

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH